What is the official website of Curium Türkiye ?

The official website of Curium Türkiye is http://www.monrol.com.

What is Curium Türkiye's cybersecurity risk score?

Curium Türkiye has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Curium Türkiye experienced?

According to Rankiteo, Curium Türkiye currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Curium Türkiye been affected by any supply chain cyber incidents ?

According to Rankiteo, Curium Türkiye has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Curium Türkiye have SOC 2 Type 1 certification ?

According to Rankiteo, Curium Türkiye is not certified under SOC 2 Type 1.

Does Curium Türkiye have SOC 2 Type 2 certification ?

According to Rankiteo, Curium Türkiye does not hold a SOC 2 Type 2 certification.

Does Curium Türkiye comply with GDPR ?

According to Rankiteo, Curium Türkiye is not listed as GDPR compliant.

Does Curium Türkiye have PCI DSS certification ?

According to Rankiteo, Curium Türkiye does not currently maintain PCI DSS compliance.

Does Curium Türkiye comply with HIPAA ?

According to Rankiteo, Curium Türkiye is not compliant with HIPAA regulations.

Does Curium Türkiye have ISO 27001 certification ?

According to Rankiteo,Curium Türkiye is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Curium Türkiye operate in ?

Curium Türkiye operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Curium Türkiye have ?

Curium Türkiye employs approximately 214 people worldwide.

Does Curium Türkiye own any subsidiaries ?

Curium Türkiye presently has no subsidiaries across any sectors.

How many LinkedIn followers does Curium Türkiye have ?

Curium Türkiye's official LinkedIn profile has approximately 18,700 followers.

What is the NAICS classification code for Curium Türkiye ?

Curium Türkiye is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Curium Türkiye have a Crunchbase profile ?

No, Curium Türkiye does not have a profile on Crunchbase.

Does Curium Türkiye have a LinkedIn profile ?

Yes, Curium Türkiye maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/curium-turkiye.

How many cybersecurity incidents has Curium Türkiye experienced ?

As of September 5, 2026, Rankiteo reports that Curium Türkiye has not experienced any cybersecurity incidents.

How many peer or competitor companies does Curium Türkiye have ?

Curium Türkiye has an estimated 5,755 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Curium Türkiye

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Curium Türkiye Vendor Cyber Rating & Cyber Score

monrol.com

Add Your Compliance Badge

Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have. As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and

Curium Türkiye A.I CyberSecurity Scoring

Scoring History

Curium Türkiye

Curium Türkiye CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Curium Türkiye Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Curium Türkiye

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Curium Türkiye in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Curium Türkiye in 2026.

Incident Types Curium Türkiye vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Curium Türkiye in 2026.

Incident History - Curium Türkiye (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Curium Türkiye Subsidiaries

Curium Türkiye

Pharmaceutical Manufacturing

Website: http://www.monrol.com

Company Size: 214

Eczacıbaşı TopluluğuManufacturing

Eczacıbaşı Yapı ÜrünleriWholesale Building Materials

VitrA KaroWholesale Building Materials

Eczacıbaşı İntemaWholesale Building Materials

Kanyon Yönetim İşletim ve Pazarlama A.Ş.Retail

EsanMining

Eczacıbaşı İlaç PazarlamaPharmaceutical Manufacturing

Loading…

Curium Türkiye Similar Companies

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Loading…

NEWS

Curium Türkiye CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-86098

SUMMARY

ntop nDPI versions before 6.0 contain a heap buffer overflow vulnerability in the ndpi_json_string_escape function that writes beyond caller-supplied buffer boundaries. Attackers can trigger the overflow by supplying crafted network packet data including TLS SNI, HTTP headers, or DNS names that reach the vulnerable function, causing heap corruption.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:H/A:H

cvss4

Base Score: 8.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:N/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.2

REFERENCES

CVE-2026-86097

SUMMARY

PX4 Autopilot through 1.17.0 contains a null pointer dereference vulnerability in param_set_default_file() and param_set_backup_file() functions that allows attackers to crash the autopilot process. Attackers can invoke 'param select' or 'param select-backup' commands with no path argument from any PX4 shell to trigger the crash.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-86096

SUMMARY

PX4 Autopilot through 1.17.0 contains a use-after-free vulnerability in TemperatureCalibration::start() due to a race condition between task spawning and object deletion. Attackers can trigger the calibration process via shell commands to write to freed heap memory, corrupting unrelated objects or allocator metadata and destabilizing heap operations.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:A/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:H

cvss4

Base Score: 6.0

Complexity: HIGH

CVSS:4.0/AV:A/AC:H/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.2

Exploitability

1.6

REFERENCES

CVE-2026-86095

SUMMARY

Unidata netcdf-c through 4.10.1 contains an out-of-bounds write vulnerability in NC4_HDF5_inq_attname() that copies HDF5 attribute names into a fixed 256-byte buffer without length validation. Attackers can craft HDF5 files with oversized attribute names to overflow the destination buffer, causing memory corruption and crashes when applications enumerate attribute names.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.5

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-48019

SUMMARY

Laravel is a web application framework. Prior to versions 12.60.0 and 13.10.0, a CRLF injection vulnerability in Laravel's email validation, in combination with how Symfony Mailer and Symfony Mime handle certain character sequences, may allow an unauthenticated attacker to interfere with outbound email processing in applications that send mail to user-supplied addresses. This issue has been patched in versions 12.60.0 and 13.10.0.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 8.9)

cvss3

Base Score: 8.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:L

Impact Score

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…